A systematic review about the role of preoperative 18F-FDG PET/CT for prognosis and risk stratification in patients with endometrial cancer

Author(s):  
Edel Noriega-Álvarez ◽  
Ana M. García Vicente ◽  
Germán A. Jiménez Londoño ◽  
Wilson R. Martínez Bravo ◽  
Beatriz González García ◽  
...  
2011 ◽  
Vol 50 (05) ◽  
pp. 204-213 ◽  
Author(s):  
H. J. Lee ◽  
C. M. Hong ◽  
B. I. Song ◽  
H. W. Kim ◽  
S. Kang ◽  
...  

SummaryThe aim of this study is to evaluate the usefulness of 18F-FDG PET/CT for preoperative stratification of high-risk and low-risk carcinomas in patients with endometrial cancer. Patients, methods: 60 women (mean age 53.8 ± 9.9 years) with endometrial cancer, who underwent 18F-FDG PET/CT for preoperative staging work-up, followed by primary cytoreductive surgery, were enrolled in this study. Maximum and mean standardized uptake values (SUVmax, SUVmean) of endometrial tumors were measured, and compared with the various clinicopathologic findings obtained after surgery. Tumour aggressiveness was classified as high-risk and low-risk carcinomas. Patients with stage I or II, endometrioid adenocarcinoma, histologic grade 1 or 2, invasion of less than half of the myometrium, maximum tumor size less than 2.0 cm, and absence of cervical invasion and lymphovascular space involvement (LVSI) were classified as the lowrisk carcinoma group. The remaining patients were classified as the high-risk carcinoma group. Results: In univariate analysis, SUVmax of the primary endometrial tumor was significantly higher in patients who were in a postmenopausal state (p = 0.047), large (> 2 cm) primary tumor (p <0.001), nonendometrioid subtype (p = 0.024), invasion of more than half of the myometrium (p = 0.020), or LVSI (p = 0.004). SUVmax differed significantly according to FIGO stage (p = 0.013) and histologic grade (p <0.001). In multivariate analysis, FIGO stage, histologic grade, LVSI, and maximum tumor size demonstrated a significant association with SUVmax (p <0.001; r = 0.843, r2 = 0.711). SUVmean showed similar results. Forty-one (68.3%) patients were diagnosed postoperatively as high-risk and 19 patients (31.7%) as low-risk carcinoma. Patients with high-risk carcinoma (12.1 ± 6.1) showed significantly higher SUVmax than patients with low-risk carcinoma (5.8 ± 2.8, p <0.001). The optimal SUVmax cut-off value of 8.7, determined by ROC analysis, revealed 75.6% sensitivity, 89.5% specificity, and 81.7% accuracy for risk stratification. Conclusion: High-risk endometrial cancer might be differentiated by means of higher SUVmax from low-risk endometrial cancer. 18F-FDG FDG PET/CT can be applied preoperatively for stratification of risk in patients with endometrial cancer.


2013 ◽  
Vol 130 (2) ◽  
pp. 306-311 ◽  
Author(s):  
Cinzia Crivellaro ◽  
Mauro Signorelli ◽  
Luca Guerra ◽  
Elena De Ponti ◽  
Cecilia Pirovano ◽  
...  

2016 ◽  
Vol 57 (6) ◽  
pp. 879-885 ◽  
Author(s):  
V. R. Bollineni ◽  
S. Ytre-Hauge ◽  
O. Bollineni-Balabay ◽  
H. B. Salvesen ◽  
I. S. Haldorsen

2020 ◽  
Vol 13 (11) ◽  
pp. 377
Author(s):  
Salvatore Annunziata ◽  
Roberto C. Delgado Bolton ◽  
Christel-Hermann Kamani ◽  
John O. Prior ◽  
Domenico Albano ◽  
...  

Some recent studies evaluated the role of fluorine-18 fluorodeoxyglucose (2-[18F]FDG) as a radiopharmaceutical for positron emission tomography/computed tomography (PET/CT) imaging in patients with Coronavirus Disease (COVID-19). This article aims to perform a systematic review in this setting. A comprehensive computer literature search in PubMed/MEDLINE and Cochrane library databases regarding the role of 2-[18F]FDG PET/CT in patients with COVID-19 was carried out. This combination of key words was used: (A) “PET” OR “positron emission tomography” AND (B) “COVID” OR “SARS”. Only pertinent original articles were selected; case reports and very small case series were excluded. We have selected 11 original studies of 2-[18F]FDG PET/CT in patients with COVID-19. Evidence-based data showed first preliminary applications of this diagnostic tool in this clinical setting, with particular regard to the incidental detection of interstitial pneumonia suspected for COVID-19. To date, according to evidence-based data, 2-[18F]FDG PET/CT cannot substitute or integrate high-resolution CT to diagnose suspicious COVID-19 or for disease monitoring, but it can only be useful to incidentally detect suspicious COVID-19 lesions in patients performing this imaging method for standard oncological and non-oncological indications. Published data about the possible role of 2-[18F]FDG PET/CT in patients with COVID-19 are increasing, but larger studies are warranted.


Radiation ◽  
2021 ◽  
Vol 1 (1) ◽  
pp. 65-76
Author(s):  
Domenico Albano ◽  
Francesco Bertagna ◽  
Francesco Dondi ◽  
Salvatore Annunziata ◽  
Luca Ceriani ◽  
...  

Richter transformation (RT) is a condition wherein B cell chronic lymphocytic leukemia (CLL) transforms into a more aggressive lymphoma variant. The incidence and the significance of RT detected by 2-[18F]-FDG PET/CT is a clinical challenge and it is not widely investigated in the literature. The aim of this systematic review was to analyze published data about the potential role of 2-[18F]-FDG PET/CT in detecting RT. A comprehensive computer literature search of the PubMed/MEDLINE, Embase and Cochrane library databases was conducted up to December 2020. Thirteen studies (1336 patients with CLL) were selected. The maximum standardized uptake value (SUVmax) was the most common metabolic parameter used to detect RT. An SUVmax of 5 had an average overall sensitivity of 87% (range: 71–96%), an average overall specificity of 49% (range: 4–80%), an average positive predictive value of 41% (range: 16–53%) and an average negative predictive value of 84% (range: 33–97%). Other metabolic variables were only marginally investigated, with promising results. 2-[18F]-FDG PET/CT imaging may play an important role in the detection of RT in CLL, based on the high metabolic activity of the nodal lesions that transformed into aggressive lymphomas. 2-[18F]-FDG PET/CT has high negative predictive value for evaluating RT.


Endocrine ◽  
2015 ◽  
Vol 51 (3) ◽  
pp. 490-498 ◽  
Author(s):  
E. M. Triviño Ibáñez ◽  
M. A. Muros ◽  
E. Torres Vela ◽  
J. M. Llamas Elvira

2015 ◽  
Vol 43 (5) ◽  
pp. 860-870 ◽  
Author(s):  
Elba C. Etchebehere ◽  
Brian P. Hobbs ◽  
Denái R. Milton ◽  
Osama Malawi ◽  
Shreyaskumar Patel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document